They Did It Again: Trump Set Another Trap for Dems on Rogue Judges
How a CNN Political Commentator Shut Down the Leftist Meltdown Over the FBI...
A Judge Was Arrested for Trying to Help an Illegal Alien Escape. Let's...
Whoever Did This to Shedeur Sanders During the NFL Draft Is Cold-Blooded
Lawless in the Courtroom
If It Saves One Life?
The Party of Racism, Prejudice, and Bias
Trump: I'm Not 'Trolling' When I Say Canada Should Join the US
Hakeem Jeffries Boasts About Blocking Citizen-Only Voting Rule
Nancy Mace Blasts Clemson’s 15-Gender Lunacy
Trump Meets With Zelensky While in Rome for Pope Francis' Funeral
These Posts From Ed Markey, Amy Klobuchar in Reaction to Judge's Arrest Were...
The U.S. Should Learn From a Diminished Europe’s Energy Mistakes
Democrats Should Love the Tax Cuts and Jobs Act
Trump’s Tax Cuts Worked — Now Make Them Permanent
OPINION

West Virginia on the Right Track to Lower Drug Costs, But is it Enough?

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
AP Photo/Matt Rourke

The GOP-controlled House of Delegates in West Virginia recently unanimously passed a bill that would require pharmacy benefit managers (PBM) to share the rebates they receive from drug companies with consumers at the point of purchase. The bill now goes to the state Senate.

Advertisement

Pharmacy benefit managers were created to administer drug benefits for health plans including commercial, employee and retiree plans and Medicare Part D.  In 2003, the PBM industry secured safe harbor status from Congress that exempted them from criminal prosecution for taking rebates from drug manufacturers. 

Essentially, PBMs can collect these kickbacks and give certain medications access to the millions of insured lives they manage over another manufacturer’s products based on how much the companies pay them. The PBMs’ priority shifted from the payer (health plans) to the seller (drug manufacturers) and created a conflict of interest. 

Patients may find the cost of their medications drastically increase due to a change in formulary tiering set by the pharmacy benefit manager. A skewed business practice emerged where PBMs are paid a percentage of the cost of the utilized drugs they manage which increases the compensation they receive for higher-priced drugs. Keep in mind that PBMs do no research and development, manufacturing or distribution. 

The West Virginia bill is admirable in that state legislators want to address the escalating price of prescription drugs and lower the out-of-pocket costs for consumers, but is it enough? AMAC – the Association of Mature Americans, along with a coalition of physician and patient advocates are working together to see the safe harbor status repealed and the middleman money removed completely from the outpatient prescription drug supply chain.

Advertisement

Drug manufacturers’ list prices are negatively affected by the kickbacks they must pay to PBMs. Removing the middleman money and the resulting many billions of dollars saved in drug costs seems like a sensible place to start the forthcoming debate on health care reform.  

Andrew Mangione is Senior Vice President at AMAC Action, the advocacy arm of AMAC – the Association of Mature American Citizens.  AMAC represents more than 2 million members and stands for fiscal responsibility. He writes on health care issues, among other concerns.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement